A practical reference on carcinogenicity: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
=== 2011–2017: The Only Way Is Essex, I'm a Celebrity...Get Me Out of Here! and Celebrity Big Brother === In January 2011, Julie Childs, mother of Collins' friend Amy, suggested to producers of the ITV2 reality series The Only Way Is Essex that Collins would be an appropriate subject. They visited Collins' house and subsequently filmed her and her friends for two weeks. After returning to work as a car sales executive for a week, she was cast in the programme and began appearing in The Only Way Is Essex from its second series beginning in March 2011. Her first scene saw her attempting to sell a car to Kirk Norcross and taking him for a test drive. Collins ultimately quit her job to appear on the programme full time, and was paid £50 a day for her early appearances on the show, which she described as a "massive risk". Her mother Joan joined the programme during the fifth series in April 2012. From September 2011 until March 2013, Collins wrote a regular column in the tabloid magazine Closer. In April 2013, she released her debut autobiography Basically...: My Life as a Real Essex Girl, which became a bestseller in its first week of release. In January 2014, Collins took part in the second series of the ITV diving competition Splash!. During training, Collins suffered severe bruising and admitted she had to overcome a fear of water. She became the third celebrity to be eliminated after losing the splash-off to Michaela Strachan in the first heat. In November 2014, she took part in the fourteenth series of I'm a Celebrity...Get Me Out of Here! on ITV.
== Chemistry == Mirtazapine is a tetracyclic piperazinoazepine; mianserin was developed by the same team of organic chemists and mirtazapine differs from it via the addition of a nitrogen atom in one of the rings. It is a racemic mixture of enantiomers. The (S)-(+)-enantiomer is known as esmirtazapine. Analogues of mirtazapine include mianserin, setiptiline, and aptazapine.
=== Gross composition === Published data on donkey milk's gross composition confirm the close resemblance to breast milk for lactose, protein, and ash levels when compared with cow, sheep and goat milk. Despite the high lactose content of donkey milk, the average fat content is lower. When used in infant nutrition, donkey milk is usually supplemented with vegetable oil (4 mL per 100 mL of milk) to conform to human milk energy.
2019: Micheal Anak Garing, a Malaysian hanged on 22 March 2019 for the murder of a construction worker during a series of armed robberies in 2010. 2025: Iskandar bin Rahmat, a former police officer hanged on 5 February 2025 for the 2013 Kovan double murders. 2025: Eric Teo Ghim Heng, a former property agent hanged on 16 April 2025 for the murder of his wife and their daughter in 2017, which became known as the Woodlands double murders.
Sources: en.wikipedia.org
== References == "Trichopsis vittata". Integrated Taxonomic Information System. Retrieved 11 March 2006. Froese, Rainer; Pauly, Daniel (eds.). "Trichopsis vittata". FishBase. February 2014 version. Ladich, F., W. Brtittenger, and H. Kratochvil (1992). Significance Of Agonistic Vocalization In The Croaking Gourami. Shafland, P. L. (1996). "Exotic Fishes of Florida-1994". Reviews in Fisheries Science 4(2). Sterba, G. (1983). The Aquarium Fish Encyclopedia. The MIT Press.
Oxford's Joint European Torus nuclear fusion laboratory conducts its final experiments after 40 years in operation. 15 October First Minister of Scotland Humza Yousaf signals a change in his party's Scottish independence strategy, now saying that an SNP win in a majority of Scotland's Westminster seats would give the party a mandate to begin independence negotiations with the Westminster Government. One person is killed and another is wounded in a stabbing attack in Hartlepool. The attack is being investigated by Counter Terrorism Policing. A suspect has been detained. 16–22 October – Storm Babet hits the UK, bringing disruption to much of the country. Red weather warnings are issued by the Met Office, as three deaths are reported, and power shortages affect tens of thousands in Scotland. The crew of a Danish fishing trawler are rescued by the RNLI in the North Sea. 16 October Prime Minister Rishi Sunak confirms that six British citizens were killed during the Hamas attacks on Israel, while a further ten are missing. Two British teenage sisters, Noya and Yahel Sharabi, are among those missing, and believed to have been kidnapped, following the 7 October attacks on Israel. Their mother, Lianne, also a British citizen, was killed in the Be'eri massacre. The following day the girls' family tells the BBC the Yahel was also murdered. On 22 October the family release a statement to say Noya was also murdered. Guardian cartoonist Steve Bell is sacked following a row over a drawing he created of Israeli prime minister Benjamin Netanyahu that was deemed to be antisemitic.
==== Protein chips ==== Balancing the use of mass spectrometers in proteomics and in medicine is the use of protein micro arrays. The aim behind protein micro arrays is to print thousands of protein detecting features for the interrogation of biological samples. Antibody arrays are an example in which a host of different antibodies are arrayed to detect their respective antigens from a sample of human blood. Another approach is the arraying of multiple protein types for the study of properties like protein-DNA, protein-protein and protein-ligand interactions. Ideally, the functional proteomic arrays would contain the entire complement of the proteins of a given organism. The first version of such arrays consisted of 5000 purified proteins from yeast deposited onto glass microscopic slides. Despite the success of the first chip, it was a greater challenge for protein arrays to be implemented. Proteins are inherently much more difficult to work with than DNA. They have a broad dynamic range, are less stable than DNA and their structure is difficult to preserve on glass slides, though they are essential for most assays. The global ICAT technology has striking advantages over protein chip technologies.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.